Metformin: a metabolic modulator

Federico Pietrocola; Guido Kroemer

doi:10.18632/oncotarget.14794

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspective: Autophagy:

Metformin: a metabolic modulator

Federico Pietrocola and Guido Kroemer _

PDF | HTML | How to cite

Oncotarget. 2017; 8:9017-9020. https://doi.org/10.18632/oncotarget.14794

Metrics: PDF 3050 views | HTML 4751 views | ?

Abstract

Federico Pietrocola1,2,3,4,5,6 and Guido Kroemer1,2,3,4,5,6,7,8

1 Gustave Roussy Comprehensive Cancer Institute, Villejuif, France

2 INSERM, U1138, Paris, France

3 Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France

4 Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France

5 Université Pierre et Marie Curie/Paris VI, Paris, France

6 Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France

7 Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France

8 Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden

Correspondence to:

Guido Kroemer, email:

Keywords: aging, autophagy, biguanides, caloric restriction, cancer

Received: January 06, 2017 Accepted: January 12, 2017 Published: January 22, 2017

Abstract

Recent findings have shed new light on the mechanisms of action through which biguanides exert their anti-aging and cytostatic effects in Caenorhabditis elegans and human cell lines. The drop in energy charge resulting from the metformin mediated inhibition of mitochondrial activity affects the function of the nuclear pore complex, blocks mTOR signaling and enhances the expression of ACAD10. Whether the inhibition of this pathway is truly responsible for the anti-diabetic and cancer effects of the drug in mammals remains to be established.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14794

Publication Alerts

Research Perspective: Autophagy:

Metformin: a metabolic modulator

Abstract